Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Issues related to the following bills: S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. S.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin.
Issues related to the following bills: S.1040: Drug Competition Enhancement Act - Prohibits product hopping which stifles generic and biosimilar competition to extend monopoly pricing. It explicitly defines and regulates these under the Federal Trade Commission S.1041: Affordable Prescriptions for Patients Act - Limits how brand-name drug companies use patents to block competition from cheaper biosimilar or generic versions of biologic drugs by reducing the number of patents drug companies can use to delay cheaper alternatives from entering the market - making medicines more affordable and accessible. A brand-name drug company could then only sue using up to 20 patents when a competitor applies to sell a biosimilar. S.1095: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act - Stops pharmaceutical companies from abusing the citizen petition process to file sham petitions to block or delay generic or biosimilar drug approvals. S.1096: Preserve Access to Affordable Generics and Biosimilars Act - Bans pay-to-delay or killer acquisitions. Brand name drug manufacturers cannot pay generic manufacturers to delay-to-market any competitive biosimilar or interchangeable biologic products. S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. HR 7854: Medicines for the People Act - To amend the Public Health Service Act to establish a National Institute for Biomedical Research and Development, and for other purposes. S.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Additionally, issues related to an FTC settlement.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
T1INTERNATIONAL USA via T1INTERNATIONAL USA
2026 · third_quarter · Q3
Issues related to the following bills: S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. S.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
T1INTERNATIONAL USA via T1INTERNATIONAL USA
2026 · second_quarter · Q2
Source: Senate LDA
Issues related to the following bills: S.1040: Drug Competition Enhancement Act - Prohibits product hopping which stifles generic and biosimilar competition to extend monopoly pricing. It explicitly defines and regulates these under the Federal Trade Commission S.1041: Affordable Prescriptions for Patients Act - Limits how brand-name drug companies use patents to block competition from cheaper biosimilar or generic versions of biologic drugs by reducing the number of patents drug companies can use to delay cheaper alternatives from entering the market - making medicines more affordable and accessible. A brand-name drug company could then only sue using up to 20 patents when a competitor applies to sell a biosimilar. S.1095: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act - Stops pharmaceutical companies from abusing the citizen petition process to file sham petitions to block or delay generic or biosimilar drug approvals. S.1096: Preserve Access to Affordable Generics and Biosimilars Act - Bans pay-to-delay or killer acquisitions. Brand name drug manufacturers cannot pay generic manufacturers to delay-to-market any competitive biosimilar or interchangeable biologic products. S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. HR 7854: Medicines for the People Act - To amend the Public Health Service Act to establish a National Institute for Biomedical Research and Development, and for other purposes. S.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Additionally, issues related to an FTC settlement.
Issues related to the following bills: S.1040: Drug Competition Enhancement Act - Prohibits product hopping which stifles generic and biosimilar competition to extend monopoly pricing. It explicitly defines and regulates these under the Federal Trade Commission S.1041: Affordable Prescriptions for Patients Act - Limits how brand-name drug companies use patents to block competition from cheaper biosimilar or generic versions of biologic drugs by reducing the number of patents drug companies can use to delay cheaper alternatives from entering the market - making medicines more affordable and accessible. A brand-name drug company could then only sue using up to 20 patents when a competitor applies to sell a biosimilar. S.1095: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act - Stops pharmaceutical companies from abusing the citizen petition process to file sham petitions to block or delay generic or biosimilar drug approvals. S.1096: Preserve Access to Affordable Generics and Biosimilars Act - Bans pay-to-delay or killer acquisitions. Brand name drug manufacturers cannot pay generic manufacturers to delay-to-market any competitive biosimilar or interchangeable biologic products. S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. HR 7854: Medicines for the People Act - To amend the Public Health Service Act to establish a National Institute for Biomedical Research and Development, and for other purposes. S.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Additionally, issues related to an FTC settlement.
Affordable Prescriptions for Patients Act
Client: T1INTERNATIONAL USA · Firm: T1INTERNATIONAL USA
Issues related to the following bills: S.1040: Drug Competition Enhancement Act - Prohibits product hopping which stifles generic and biosimilar competition to extend monopoly pricing. It explicitly defines and regulates these under the Federal Trade Commission S.1041: Affordable Prescriptions for Patients Act - Limits how brand-name drug companies use patents to block competition from cheaper biosimilar or generic versions of biologic drugs by reducing the number of patents drug companies can use to delay cheaper alternatives from entering the market - making medicines more affordable and accessible. A brand-name drug company could then only sue using up to 20 patents when a competitor applies to sell a biosimilar. S.1095: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act - Stops pharmaceutical companies from abusing the citizen petition process to file sham petitions to block or delay generic or biosimilar drug approvals. S.1096: Preserve Access to Affordable Generics and Biosimilars Act - Bans pay-to-delay or killer acquisitions. Brand name drug manufacturers cannot pay generic manufacturers to delay-to-market any competitive biosimilar or interchangeable biologic products. S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. HR 7854: Medicines for the People Act - To amend the Public Health Service Act to establish a National Institute for Biomedical Research and Development, and for other purposes. S.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Additionally, issues related to an FTC settlement.
Issues related to the following bills: S.1040: Drug Competition Enhancement Act - Prohibits product hopping which stifles generic and biosimilar competition to extend monopoly pricing. It explicitly defines and regulates these under the Federal Trade Commission S.1041: Affordable Prescriptions for Patients Act - Limits how brand-name drug companies use patents to block competition from cheaper biosimilar or generic versions of biologic drugs by reducing the number of patents drug companies can use to delay cheaper alternatives from entering the market - making medicines more affordable and accessible. A brand-name drug company could then only sue using up to 20 patents when a competitor applies to sell a biosimilar. S.1095: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act - Stops pharmaceutical companies from abusing the citizen petition process to file sham petitions to block or delay generic or biosimilar drug approvals. S.1096: Preserve Access to Affordable Generics and Biosimilars Act - Bans pay-to-delay or killer acquisitions. Brand name drug manufacturers cannot pay generic manufacturers to delay-to-market any competitive biosimilar or interchangeable biologic products. S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. HR 7854: Medicines for the People Act - To amend the Public Health Service Act to establish a National Institute for Biomedical Research and Development, and for other purposes. S.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Additionally, issues related to an FTC settlement.
Preserve Access to Affordable Generics and Biosimilars Act
Client: T1INTERNATIONAL USA · Firm: T1INTERNATIONAL USA
Issues related to the following bills: S.1040: Drug Competition Enhancement Act - Prohibits product hopping which stifles generic and biosimilar competition to extend monopoly pricing. It explicitly defines and regulates these under the Federal Trade Commission S.1041: Affordable Prescriptions for Patients Act - Limits how brand-name drug companies use patents to block competition from cheaper biosimilar or generic versions of biologic drugs by reducing the number of patents drug companies can use to delay cheaper alternatives from entering the market - making medicines more affordable and accessible. A brand-name drug company could then only sue using up to 20 patents when a competitor applies to sell a biosimilar. S.1095: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act - Stops pharmaceutical companies from abusing the citizen petition process to file sham petitions to block or delay generic or biosimilar drug approvals. S.1096: Preserve Access to Affordable Generics and Biosimilars Act - Bans pay-to-delay or killer acquisitions. Brand name drug manufacturers cannot pay generic manufacturers to delay-to-market any competitive biosimilar or interchangeable biologic products. S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. HR 7854: Medicines for the People Act - To amend the Public Health Service Act to establish a National Institute for Biomedical Research and Development, and for other purposes. S.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Additionally, issues related to an FTC settlement.
Issues related to the following bills: S.1040: Drug Competition Enhancement Act - Prohibits product hopping which stifles generic and biosimilar competition to extend monopoly pricing. It explicitly defines and regulates these under the Federal Trade Commission S.1041: Affordable Prescriptions for Patients Act - Limits how brand-name drug companies use patents to block competition from cheaper biosimilar or generic versions of biologic drugs by reducing the number of patents drug companies can use to delay cheaper alternatives from entering the market - making medicines more affordable and accessible. A brand-name drug company could then only sue using up to 20 patents when a competitor applies to sell a biosimilar. S.1095: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act - Stops pharmaceutical companies from abusing the citizen petition process to file sham petitions to block or delay generic or biosimilar drug approvals. S.1096: Preserve Access to Affordable Generics and Biosimilars Act - Bans pay-to-delay or killer acquisitions. Brand name drug manufacturers cannot pay generic manufacturers to delay-to-market any competitive biosimilar or interchangeable biologic products. S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. HR 7854: Medicines for the People Act - To amend the Public Health Service Act to establish a National Institute for Biomedical Research and Development, and for other purposes. S.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Additionally, issues related to an FTC settlement.
Issues related to the following bills: oAffordable Drug Manufacturing Act (no bill number yet) - To establish an Office of Drug Manufacturing within HHS and for them to manufacture generic drugs that the federal government has licensed. oS.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. oH.R.3269/S.2276: ETHIC Act - would curb the practice of patent thicketing, bringing competition to the domestic biosimilars market and increasing access to lower cost treatments and cures.
Issues related to the following bills: S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. S.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin.
Issues related to the following bills: S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. S.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin.
Issues related to the following bills: S.1040: Drug Competition Enhancement Act - Prohibits product hopping which stifles generic and biosimilar competition to extend monopoly pricing. It explicitly defines and regulates these under the Federal Trade Commission S.1041: Affordable Prescriptions for Patients Act - Limits how brand-name drug companies use patents to block competition from cheaper biosimilar or generic versions of biologic drugs by reducing the number of patents drug companies can use to delay cheaper alternatives from entering the market - making medicines more affordable and accessible. A brand-name drug company could then only sue using up to 20 patents when a competitor applies to sell a biosimilar. S.1095: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act - Stops pharmaceutical companies from abusing the citizen petition process to file sham petitions to block or delay generic or biosimilar drug approvals. S.1096: Preserve Access to Affordable Generics and Biosimilars Act - Bans pay-to-delay or killer acquisitions. Brand name drug manufacturers cannot pay generic manufacturers to delay-to-market any competitive biosimilar or interchangeable biologic products. S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. HR 7854: Medicines for the People Act - To amend the Public Health Service Act to establish a National Institute for Biomedical Research and Development, and for other purposes. S.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Additionally, issues related to an FTC settlement.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: T1INTERNATIONAL USA · Firm: T1INTERNATIONAL USA
Issues related to the following bills: H.R. 1, One Big Beautiful Bill - Subtitle D (Health), Part 1 (Medicaid), S. 1040, regarding product hopping; S. 1041, regarding patent evergreening; S. 1095, the Stop STALLING Act; S. 1096, the Preserve Access to Affordable Generics and Biosimilars Act; H.R. 3160/S.1553, the PREVAIL Act; H.R. 3152/S.1546, the PERA Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: T1INTERNATIONAL USA · Firm: T1INTERNATIONAL USA
Issues related to the following bills: oBig Beautiful Bill (HR 1) oDrug Competition Enhancement Act (S.1040) oAffordable Prescriptions for Patients Act (S.1041) oStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act (S.1095) oPreserve Access to Affordable Generics and Biosimilars Act (S.1096) oPromoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (H.R.3160/S.1553): oPatent Eligibility Restoration (PERA) Act (H.R.3152/S.1546) oPrescription Drug Price Relief Act (S.1818) oEnd Price Gouging for Medications Act (S.1753) oFair Prescription Drug Prices for Americans Act (S.1218)
Patent Eligibility Restoration Act of 2025
Client: T1INTERNATIONAL USA · Firm: T1INTERNATIONAL USA
Issues related to the following bills: oBig Beautiful Bill (HR 1) oDrug Competition Enhancement Act (S.1040) oAffordable Prescriptions for Patients Act (S.1041) oStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act (S.1095) oPreserve Access to Affordable Generics and Biosimilars Act (S.1096) oPromoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (H.R.3160/S.1553): oPatent Eligibility Restoration (PERA) Act (H.R.3152/S.1546) oPrescription Drug Price Relief Act (S.1818) oEnd Price Gouging for Medications Act (S.1753) oFair Prescription Drug Prices for Americans Act (S.1218)
Patent Eligibility Restoration Act of 2025
Client: T1INTERNATIONAL USA · Firm: T1INTERNATIONAL USA
Issues related to the following bills: H.R. 1, One Big Beautiful Bill - Subtitle D (Health), Part 1 (Medicaid), S. 1040, regarding product hopping; S. 1041, regarding patent evergreening; S. 1095, the Stop STALLING Act; S. 1096, the Preserve Access to Affordable Generics and Biosimilars Act; H.R. 3160/S.1553, the PREVAIL Act; H.R. 3152/S.1546, the PERA Act
Issues related to the following bills: oBig Beautiful Bill (HR 1) oDrug Competition Enhancement Act (S.1040) oAffordable Prescriptions for Patients Act (S.1041) oStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act (S.1095) oPreserve Access to Affordable Generics and Biosimilars Act (S.1096) oPromoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (H.R.3160/S.1553): oPatent Eligibility Restoration (PERA) Act (H.R.3152/S.1546) oPrescription Drug Price Relief Act (S.1818) oEnd Price Gouging for Medications Act (S.1753) oFair Prescription Drug Prices for Americans Act (S.1218)
Issues related to the following bills: H.R. 1, One Big Beautiful Bill - Subtitle D (Health), Part 1 (Medicaid), S. 1040, regarding product hopping; S. 1041, regarding patent evergreening; S. 1095, the Stop STALLING Act; S. 1096, the Preserve Access to Affordable Generics and Biosimilars Act; H.R. 3160/S.1553, the PREVAIL Act; H.R. 3152/S.1546, the PERA Act
Issues related to the following bills: S. 1040, regarding product hopping; S. 1041, regarding patent evergreening; S. 1095, the Stop STALLING Act; S. 1096, the Preserve Access to Affordable Generics and Biosimilars Act; and a to-be-introduced bill on insulin copays in line with The INSULIN Act of 2023 (S. 1269) and Affordable Insulin Now Act of 2023 (S. 954)
Issues related to the following bills: oBig Beautiful Bill (HR 1) oDrug Competition Enhancement Act (S.1040) oAffordable Prescriptions for Patients Act (S.1041) oStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act (S.1095) oPreserve Access to Affordable Generics and Biosimilars Act (S.1096) oPromoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (H.R.3160/S.1553): oPatent Eligibility Restoration (PERA) Act (H.R.3152/S.1546) oPrescription Drug Price Relief Act (S.1818) oEnd Price Gouging for Medications Act (S.1753) oFair Prescription Drug Prices for Americans Act (S.1218)
Issues related to the following bills: H.R. 1, One Big Beautiful Bill - Subtitle D (Health), Part 1 (Medicaid), S. 1040, regarding product hopping; S. 1041, regarding patent evergreening; S. 1095, the Stop STALLING Act; S. 1096, the Preserve Access to Affordable Generics and Biosimilars Act; H.R. 3160/S.1553, the PREVAIL Act; H.R. 3152/S.1546, the PERA Act
Affordable Prescriptions for Patients Act
Client: T1INTERNATIONAL USA · Firm: T1INTERNATIONAL USA
Issues related to the following bills: oBig Beautiful Bill (HR 1) oDrug Competition Enhancement Act (S.1040) oAffordable Prescriptions for Patients Act (S.1041) oStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act (S.1095) oPreserve Access to Affordable Generics and Biosimilars Act (S.1096) oPromoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (H.R.3160/S.1553): oPatent Eligibility Restoration (PERA) Act (H.R.3152/S.1546) oPrescription Drug Price Relief Act (S.1818) oEnd Price Gouging for Medications Act (S.1753) oFair Prescription Drug Prices for Americans Act (S.1218)
Affordable Prescriptions for Patients Act
Client: T1INTERNATIONAL USA · Firm: T1INTERNATIONAL USA
Issues related to the following bills: S. 1040, regarding product hopping; S. 1041, regarding patent evergreening; S. 1095, the Stop STALLING Act; S. 1096, the Preserve Access to Affordable Generics and Biosimilars Act; and a to-be-introduced bill on insulin copays in line with The INSULIN Act of 2023 (S. 1269) and Affordable Insulin Now Act of 2023 (S. 954)
Affordable Prescriptions for Patients Act
Client: T1INTERNATIONAL USA · Firm: T1INTERNATIONAL USA
Issues related to the following bills: H.R. 1, One Big Beautiful Bill - Subtitle D (Health), Part 1 (Medicaid), S. 1040, regarding product hopping; S. 1041, regarding patent evergreening; S. 1095, the Stop STALLING Act; S. 1096, the Preserve Access to Affordable Generics and Biosimilars Act; H.R. 3160/S.1553, the PREVAIL Act; H.R. 3152/S.1546, the PERA Act
Issues related to the following bills: oBig Beautiful Bill (HR 1) oDrug Competition Enhancement Act (S.1040) oAffordable Prescriptions for Patients Act (S.1041) oStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act (S.1095) oPreserve Access to Affordable Generics and Biosimilars Act (S.1096) oPromoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (H.R.3160/S.1553): oPatent Eligibility Restoration (PERA) Act (H.R.3152/S.1546) oPrescription Drug Price Relief Act (S.1818) oEnd Price Gouging for Medications Act (S.1753) oFair Prescription Drug Prices for Americans Act (S.1218)
Issues related to the following bills: H.R. 1, One Big Beautiful Bill - Subtitle D (Health), Part 1 (Medicaid), S. 1040, regarding product hopping; S. 1041, regarding patent evergreening; S. 1095, the Stop STALLING Act; S. 1096, the Preserve Access to Affordable Generics and Biosimilars Act; H.R. 3160/S.1553, the PREVAIL Act; H.R. 3152/S.1546, the PERA Act
Issues related to the following bills: S. 1040, regarding product hopping; S. 1041, regarding patent evergreening; S. 1095, the Stop STALLING Act; S. 1096, the Preserve Access to Affordable Generics and Biosimilars Act; and a to-be-introduced bill on insulin copays in line with The INSULIN Act of 2023 (S. 1269) and Affordable Insulin Now Act of 2023 (S. 954)
Preserve Access to Affordable Generics and Biosimilars Act
Client: T1INTERNATIONAL USA · Firm: T1INTERNATIONAL USA
Issues related to the following bills: oBig Beautiful Bill (HR 1) oDrug Competition Enhancement Act (S.1040) oAffordable Prescriptions for Patients Act (S.1041) oStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act (S.1095) oPreserve Access to Affordable Generics and Biosimilars Act (S.1096) oPromoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (H.R.3160/S.1553): oPatent Eligibility Restoration (PERA) Act (H.R.3152/S.1546) oPrescription Drug Price Relief Act (S.1818) oEnd Price Gouging for Medications Act (S.1753) oFair Prescription Drug Prices for Americans Act (S.1218)
Preserve Access to Affordable Generics and Biosimilars Act
Client: T1INTERNATIONAL USA · Firm: T1INTERNATIONAL USA
Issues related to the following bills: S. 1040, regarding product hopping; S. 1041, regarding patent evergreening; S. 1095, the Stop STALLING Act; S. 1096, the Preserve Access to Affordable Generics and Biosimilars Act; and a to-be-introduced bill on insulin copays in line with The INSULIN Act of 2023 (S. 1269) and Affordable Insulin Now Act of 2023 (S. 954)
Preserve Access to Affordable Generics and Biosimilars Act
Client: T1INTERNATIONAL USA · Firm: T1INTERNATIONAL USA
Issues related to the following bills: H.R. 1, One Big Beautiful Bill - Subtitle D (Health), Part 1 (Medicaid), S. 1040, regarding product hopping; S. 1041, regarding patent evergreening; S. 1095, the Stop STALLING Act; S. 1096, the Preserve Access to Affordable Generics and Biosimilars Act; H.R. 3160/S.1553, the PREVAIL Act; H.R. 3152/S.1546, the PERA Act
Patent Eligibility Restoration Act of 2025
Client: T1INTERNATIONAL USA · Firm: T1INTERNATIONAL USA
Issues related to the following bills: oS.1040: Drug Competition Enhancement Act oS.1041: Affordable Prescriptions for Patients Act oS.1095: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act oS.1096: Preserve Access to Affordable Generics and Biosimilars Act oH.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act oH.R.3152/S.1546: Patent Eligibility Restoration (PERA) Act oH.R.3269: ETHIC Act
Patent Eligibility Restoration Act of 2025
Client: T1INTERNATIONAL USA · Firm: T1INTERNATIONAL USA
Issues related to the following bills: oBig Beautiful Bill (HR 1) oDrug Competition Enhancement Act (S.1040) oAffordable Prescriptions for Patients Act (S.1041) oStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act (S.1095) oPreserve Access to Affordable Generics and Biosimilars Act (S.1096) oPromoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (H.R.3160/S.1553): oPatent Eligibility Restoration (PERA) Act (H.R.3152/S.1546) oPrescription Drug Price Relief Act (S.1818) oEnd Price Gouging for Medications Act (S.1753) oFair Prescription Drug Prices for Americans Act (S.1218)
Patent Eligibility Restoration Act of 2025
Client: T1INTERNATIONAL USA · Firm: T1INTERNATIONAL USA
Issues related to the following bills: H.R. 1, One Big Beautiful Bill - Subtitle D (Health), Part 1 (Medicaid), S. 1040, regarding product hopping; S. 1041, regarding patent evergreening; S. 1095, the Stop STALLING Act; S. 1096, the Preserve Access to Affordable Generics and Biosimilars Act; H.R. 3160/S.1553, the PREVAIL Act; H.R. 3152/S.1546, the PERA Act
Issues related to the following bills: H.R. 1, One Big Beautiful Bill - Subtitle D (Health), Part 1 (Medicaid), S. 1040, regarding product hopping; S. 1041, regarding patent evergreening; S. 1095, the Stop STALLING Act; S. 1096, the Preserve Access to Affordable Generics and Biosimilars Act; H.R. 3160/S.1553, the PREVAIL Act; H.R. 3152/S.1546, the PERA Act
Issues related to the following bills: oBig Beautiful Bill (HR 1) oDrug Competition Enhancement Act (S.1040) oAffordable Prescriptions for Patients Act (S.1041) oStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act (S.1095) oPreserve Access to Affordable Generics and Biosimilars Act (S.1096) oPromoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (H.R.3160/S.1553): oPatent Eligibility Restoration (PERA) Act (H.R.3152/S.1546) oPrescription Drug Price Relief Act (S.1818) oEnd Price Gouging for Medications Act (S.1753) oFair Prescription Drug Prices for Americans Act (S.1218)
Issues related to the following bills: oS.1040: Drug Competition Enhancement Act oS.1041: Affordable Prescriptions for Patients Act oS.1095: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act oS.1096: Preserve Access to Affordable Generics and Biosimilars Act oH.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act oH.R.3152/S.1546: Patent Eligibility Restoration (PERA) Act oH.R.3269: ETHIC Act
Issues related to the following bills: oBig Beautiful Bill (HR 1) oDrug Competition Enhancement Act (S.1040) oAffordable Prescriptions for Patients Act (S.1041) oStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act (S.1095) oPreserve Access to Affordable Generics and Biosimilars Act (S.1096) oPromoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (H.R.3160/S.1553): oPatent Eligibility Restoration (PERA) Act (H.R.3152/S.1546) oPrescription Drug Price Relief Act (S.1818) oEnd Price Gouging for Medications Act (S.1753) oFair Prescription Drug Prices for Americans Act (S.1218)
Prescription Drug Price Relief Act of 2025
Client: T1INTERNATIONAL USA · Firm: T1INTERNATIONAL USA
Issues related to the following bills: oBig Beautiful Bill (HR 1) oDrug Competition Enhancement Act (S.1040) oAffordable Prescriptions for Patients Act (S.1041) oStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act (S.1095) oPreserve Access to Affordable Generics and Biosimilars Act (S.1096) oPromoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (H.R.3160/S.1553): oPatent Eligibility Restoration (PERA) Act (H.R.3152/S.1546) oPrescription Drug Price Relief Act (S.1818) oEnd Price Gouging for Medications Act (S.1753) oFair Prescription Drug Prices for Americans Act (S.1218)
Fair Prescription Drug Prices for Americans Act
Client: T1INTERNATIONAL USA · Firm: T1INTERNATIONAL USA
Issues related to the following bills: oBig Beautiful Bill (HR 1) oDrug Competition Enhancement Act (S.1040) oAffordable Prescriptions for Patients Act (S.1041) oStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act (S.1095) oPreserve Access to Affordable Generics and Biosimilars Act (S.1096) oPromoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (H.R.3160/S.1553): oPatent Eligibility Restoration (PERA) Act (H.R.3152/S.1546) oPrescription Drug Price Relief Act (S.1818) oEnd Price Gouging for Medications Act (S.1753) oFair Prescription Drug Prices for Americans Act (S.1218)
Issues related to the following bills: S. 1040, regarding product hopping; S. 1041, regarding patent evergreening; S. 1095, the Stop STALLING Act; S. 1096, the Preserve Access to Affordable Generics and Biosimilars Act; and a to-be-introduced bill on insulin copays in line with The INSULIN Act of 2023 (S. 1269) and Affordable Insulin Now Act of 2023 (S. 954)
Issues related to the following bills: S. 1040, regarding product hopping; S. 1041, regarding patent evergreening; S. 1095, the Stop STALLING Act; S. 1096, the Preserve Access to Affordable Generics and Biosimilars Act; and a to-be-introduced bill on insulin copays in line with The INSULIN Act of 2023 (S. 1269) and Affordable Insulin Now Act of 2023 (S. 954)
S. 954 Affordable Insulin Now Act of 2023 and related administrative action
S. 954 Affordable Insulin Now Act of 2023 and related administrative action
Insulin for All Act of 2023 (H.R. 1485/S. 727); Affordable Insulin Now Act of 2023 (S. 954)
Prescription Pricing for the People Act of 2023
Client: T1INTERNATIONAL USA · Firm: T1INTERNATIONAL USA
S. 954 Affordable Insulin for All Act of 2023; S. 727 Insulin for All Act of 2023; S. 150 Affordable Prescriptions for Patients Act of 2023; S. 148 Stop Stalling Act of 2023; S. 142 Preserve Access to Affordable Generics & Biosimilars Act; S. 113 Prescription Pricing for the People Act of 2023; S. 79 Interagency Patent Coordination and Improvement; S. 1139 Lower Drug Costs for Families Act of 2023; S. 1264 Smart Prices Act of 2023; ISLET Act; Supplies Act (Forthcoming Bill); S. 1283 Tax on Wall Street Speculation Act of 2023.
S. 954 Affordable Insulin for All Act of 2023; S. 727 Insulin for All Act of 2023; S. 150 Affordable Prescriptions for Patients Act of 2023; S. 148 Stop Stalling Act of 2023; S. 142 Preserve Access to Affordable Generics & Biosimilars Act; S. 113 Prescription Pricing for the People Act of 2023; S. 79 Interagency Patent Coordination and Improvement; S. 1139 Lower Drug Costs for Families Act of 2023; S. 1264 Smart Prices Act of 2023; ISLET Act; Supplies Act (Forthcoming Bill); S. 1283 Tax on Wall Street Speculation Act of 2023.
S. 954 Affordable Insulin for All Act of 2023; S. 727 Insulin for All Act of 2023; S. 150 Affordable Prescriptions for Patients Act of 2023; S. 148 Stop Stalling Act of 2023; S. 142 Preserve Access to Affordable Generics & Biosimilars Act; S. 113 Prescription Pricing for the People Act of 2023; S. 79 Interagency Patent Coordination and Improvement; S. 1139 Lower Drug Costs for Families Act of 2023; S. 1264 Smart Prices Act of 2023; ISLET Act; Supplies Act (Forthcoming Bill); S. 1283 Tax on Wall Street Speculation Act of 2023.
S. 954 Affordable Insulin for All Act of 2023; S. 727 Insulin for All Act of 2023; S. 150 Affordable Prescriptions for Patients Act of 2023; S. 148 Stop Stalling Act of 2023; S. 142 Preserve Access to Affordable Generics & Biosimilars Act; S. 113 Prescription Pricing for the People Act of 2023; S. 79 Interagency Patent Coordination and Improvement; S. 1139 Lower Drug Costs for Families Act of 2023; S. 1264 Smart Prices Act of 2023; ISLET Act; Supplies Act (Forthcoming Bill); S. 1283 Tax on Wall Street Speculation Act of 2023.
Preserve Access to Affordable Generics and Biosimilars Act
Client: T1INTERNATIONAL USA · Firm: T1INTERNATIONAL USA
S. 954 Affordable Insulin for All Act of 2023; S. 727 Insulin for All Act of 2023; S. 150 Affordable Prescriptions for Patients Act of 2023; S. 148 Stop Stalling Act of 2023; S. 142 Preserve Access to Affordable Generics & Biosimilars Act; S. 113 Prescription Pricing for the People Act of 2023; S. 79 Interagency Patent Coordination and Improvement; S. 1139 Lower Drug Costs for Families Act of 2023; S. 1264 Smart Prices Act of 2023; ISLET Act; Supplies Act (Forthcoming Bill); S. 1283 Tax on Wall Street Speculation Act of 2023.
S. 954 Affordable Insulin for All Act of 2023; S. 727 Insulin for All Act of 2023; S. 150 Affordable Prescriptions for Patients Act of 2023; S. 148 Stop Stalling Act of 2023; S. 142 Preserve Access to Affordable Generics & Biosimilars Act; S. 113 Prescription Pricing for the People Act of 2023; S. 79 Interagency Patent Coordination and Improvement; S. 1139 Lower Drug Costs for Families Act of 2023; S. 1264 Smart Prices Act of 2023; ISLET Act; Supplies Act (Forthcoming Bill); S. 1283 Tax on Wall Street Speculation Act of 2023.
Affordable Prescriptions for Patients Act of 2023
Client: T1INTERNATIONAL USA · Firm: T1INTERNATIONAL USA
S. 954 Affordable Insulin for All Act of 2023; S. 727 Insulin for All Act of 2023; S. 150 Affordable Prescriptions for Patients Act of 2023; S. 148 Stop Stalling Act of 2023; S. 142 Preserve Access to Affordable Generics & Biosimilars Act; S. 113 Prescription Pricing for the People Act of 2023; S. 79 Interagency Patent Coordination and Improvement; S. 1139 Lower Drug Costs for Families Act of 2023; S. 1264 Smart Prices Act of 2023; ISLET Act; Supplies Act (Forthcoming Bill); S. 1283 Tax on Wall Street Speculation Act of 2023.
S. 954 Affordable Insulin for All Act of 2023; S. 727 Insulin for All Act of 2023
S. 954 Affordable Insulin for All Act of 2023; S. 727 Insulin for All Act of 2023; S. 150 Affordable Prescriptions for Patients Act of 2023; S. 148 Stop Stalling Act of 2023; S. 142 Preserve Access to Affordable Generics & Biosimilars Act; S. 113 Prescription Pricing for the People Act of 2023; S. 79 Interagency Patent Coordination and Improvement; S. 1139 Lower Drug Costs for Families Act of 2023; S. 1264 Smart Prices Act of 2023; ISLET Act; Supplies Act (Forthcoming Bill); S. 1283 Tax on Wall Street Speculation Act of 2023.
S. 954 Affordable Insulin for All Act of 2023; S. 727 Insulin for All Act of 2023; Public Production Policies including the forthcoming Affordable Drug Manufacturing Act of 2023
Insulin for All Act of 2023 (H.R. 1485/S. 727); Affordable Insulin Now Act of 2023 (S. 954)
Interagency Patent Coordination and Improvement Act of 2023
Client: T1INTERNATIONAL USA · Firm: T1INTERNATIONAL USA
S. 954 Affordable Insulin for All Act of 2023; S. 727 Insulin for All Act of 2023; S. 150 Affordable Prescriptions for Patients Act of 2023; S. 148 Stop Stalling Act of 2023; S. 142 Preserve Access to Affordable Generics & Biosimilars Act; S. 113 Prescription Pricing for the People Act of 2023; S. 79 Interagency Patent Coordination and Improvement; S. 1139 Lower Drug Costs for Families Act of 2023; S. 1264 Smart Prices Act of 2023; ISLET Act; Supplies Act (Forthcoming Bill); S. 1283 Tax on Wall Street Speculation Act of 2023.
S. 954 Affordable Insulin for All Act of 2023; S. 727 Insulin for All Act of 2023; S. 150 Affordable Prescriptions for Patients Act of 2023; S. 148 Stop Stalling Act of 2023; S. 142 Preserve Access to Affordable Generics & Biosimilars Act; S. 113 Prescription Pricing for the People Act of 2023; S. 79 Interagency Patent Coordination and Improvement; S. 1139 Lower Drug Costs for Families Act of 2023; S. 1264 Smart Prices Act of 2023; ISLET Act; Supplies Act (Forthcoming Bill); S. 1283 Tax on Wall Street Speculation Act of 2023.
Insulin for All Act of 2023 (H.R. 1485/S. 727); Affordable Insulin Now Act of 2023 (S. 954)
S. 954 Affordable Insulin for All Act of 2023; S. 727 Insulin for All Act of 2023
S. 954 Affordable Insulin for All Act of 2023; S. 727 Insulin for All Act of 2023; Public Production Policies including the forthcoming Affordable Drug Manufacturing Act of 2023
Build Back Better Act (H.R.5376); Affordable Insulin Now Act (H.R.6833/S.3700); Affordable Insulin for All Act (no bill number)
Build Back Better Act (H.R.5376); Affordable Insulin Now Act (H.R.6833/S.3700); Affordable Insulin for All Act (no bill number)
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: T1INTERNATIONAL USA · Firm: T1INTERNATIONAL USA
Build Back Better Act (H.R.5376); Affordable Insulin Now Act (H.R.6833/S.3700); Affordable Insulin for All Act (no bill number)
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: T1INTERNATIONAL USA · Firm: T1INTERNATIONAL USA
Affordable Insulin Now Act (H.R.6833/S.3700); Affordable Insulin for All Act (no bill number); NDAA (Public Production Amendment 203); Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act (no bill number)
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: T1INTERNATIONAL USA · Firm: T1INTERNATIONAL USA
Affordable Insulin Now Act (H.R.6833/S.3700); Affordable Insulin for All Act (no bill number)
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: T1INTERNATIONAL USA · Firm: T1INTERNATIONAL USA
Build Back Better Act (H.R.5376); Affordable Insulin Now Act (H.R.6833/S.3700); Affordable Insulin for All Act (no bill number)
Restoring the America Invents Act (S.2891)
Restoring the America Invents Act (S.2891)
Build Back Better Act (H.R.5376); Affordable Insulin Now Act (H.R.6833/S.3700); Affordable Insulin for All Act (no bill number)
Build Back Better Act (H.R.5376); Affordable Insulin Now Act (H.R.6833/S.3700); Affordable Insulin for All Act (no bill number)
Affordable Insulin Now Act (H.R.6833/S.3700); Affordable Insulin for All Act (no bill number); NDAA (Public Production Amendment 203); Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act (no bill number)
Affordable Insulin Now Act (H.R.6833/S.3700); Affordable Insulin for All Act (no bill number)
Elijah E. Cummings Lower Drug Costs Now Act
Client: T1INTERNATIONAL USA · Firm: T1INTERNATIONAL USA
Build Back Better Act (H.R.5376); Elijah E. Cummings Lower Drug Costs Now Act (H.R.3); Insulin Affordability for All Act (no bill number)
Elijah E. Cummings Lower Drug Costs Now Act
Client: T1INTERNATIONAL USA · Firm: T1INTERNATIONAL USA
Build Back Better Act (H.R.5376); Elijah E. Cummings Lower Drug Costs Now Act (H.R.3); Insulin Affordability for All Act (no bill number)
Build Back Better Act (H.R.5376); Elijah E. Cummings Lower Drug Costs Now Act (H.R.3); Insulin Affordability for All Act (no bill number)
Build Back Better Act (H.R.5376); Elijah E. Cummings Lower Drug Costs Now Act (H.R.3); Insulin Affordability for All Act (no bill number)
Issues related to the following bills: oAffordable Drug Manufacturing Act (no bill number yet) - To establish an Office of Drug Manufacturing within HHS and for them to manufacture generic drugs that the federal government has licensed. oS.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. oH.R.3269/S.2276: ETHIC Act - would curb the practice of patent thicketing, bringing competition to the domestic biosimilars market and increasing access to lower cost treatments and cures.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
T1INTERNATIONAL USA via T1INTERNATIONAL USA
2026 · first_quarter · Q1
Issues related to the following bills: S.1040: Drug Competition Enhancement Act - Prohibits product hopping which stifles generic and biosimilar competition to extend monopoly pricing. It explicitly defines and regulates these under the Federal Trade Commission S.1041: Affordable Prescriptions for Patients Act - Limits how brand-name drug companies use patents to block competition from cheaper biosimilar or generic versions of biologic drugs by reducing the number of patents drug companies can use to delay cheaper alternatives from entering the market - making medicines more affordable and accessible. A brand-name drug company could then only sue using up to 20 patents when a competitor applies to sell a biosimilar. S.1095: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act - Stops pharmaceutical companies from abusing the citizen petition process to file sham petitions to block or delay generic or biosimilar drug approvals. S.1096: Preserve Access to Affordable Generics and Biosimilars Act - Bans pay-to-delay or killer acquisitions. Brand name drug manufacturers cannot pay generic manufacturers to delay-to-market any competitive biosimilar or interchangeable biologic products. S.2276/HR 3269: ETHIC Act - A bill to address patent thickets. HR 7854: Medicines for the People Act - To amend the Public Health Service Act to establish a National Institute for Biomedical Research and Development, and for other purposes. S.4189: INSULIN Act - To reduce the price of insulin and provide for patient protections with respect to the cost of insulin. Additionally, issues related to an FTC settlement.
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
T1INTERNATIONAL USA via T1INTERNATIONAL USA
2025 · fourth_quarter · Q4
Issues related to the following bills: oS.1040: Drug Competition Enhancement Act oS.1041: Affordable Prescriptions for Patients Act oS.1095: Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act oS.1096: Preserve Access to Affordable Generics and Biosimilars Act oH.R.3160/S.1553: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act oH.R.3152/S.1546: Patent Eligibility Restoration (PERA) Act oH.R.3269: ETHIC Act
Filing targets: HOUSE OF REPRESENTATIVES
T1INTERNATIONAL USA via T1INTERNATIONAL USA
2025 · third_quarter · Q3
Issues related to the following bills: oBig Beautiful Bill (HR 1) oDrug Competition Enhancement Act (S.1040) oAffordable Prescriptions for Patients Act (S.1041) oStop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act (S.1095) oPreserve Access to Affordable Generics and Biosimilars Act (S.1096) oPromoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act (H.R.3160/S.1553): oPatent Eligibility Restoration (PERA) Act (H.R.3152/S.1546) oPrescription Drug Price Relief Act (S.1818) oEnd Price Gouging for Medications Act (S.1753) oFair Prescription Drug Prices for Americans Act (S.1218)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
T1INTERNATIONAL USA via T1INTERNATIONAL USA
2025 · second_quarter · Q2
Issues related to the following bills: H.R. 1, One Big Beautiful Bill - Subtitle D (Health), Part 1 (Medicaid), S. 1040, regarding product hopping; S. 1041, regarding patent evergreening; S. 1095, the Stop STALLING Act; S. 1096, the Preserve Access to Affordable Generics and Biosimilars Act; H.R. 3160/S.1553, the PREVAIL Act; H.R. 3152/S.1546, the PERA Act
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
T1INTERNATIONAL USA via T1INTERNATIONAL USA
2025 · first_quarter · Q1
Issues related to the following bills: S. 1040, regarding product hopping; S. 1041, regarding patent evergreening; S. 1095, the Stop STALLING Act; S. 1096, the Preserve Access to Affordable Generics and Biosimilars Act; and a to-be-introduced bill on insulin copays in line with The INSULIN Act of 2023 (S. 1269) and Affordable Insulin Now Act of 2023 (S. 954)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
T1INTERNATIONAL USA via T1INTERNATIONAL USA
2024 · second_quarter · 2A
S. 954 Affordable Insulin Now Act of 2023 and related administrative action
Filing targets: Federal Trade Commission (FTC), SENATE
T1INTERNATIONAL USA via T1INTERNATIONAL USA
2024 · fourth_quarter · Q4
General issues regarding legislation related to healthcare.
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
T1INTERNATIONAL USA via T1INTERNATIONAL USA
2024 · third_quarter · Q3
The Affordable Insulin Now Act, amendments in the National Defense Authorization Act regarding publicly manufacturing insulin, and issues related to weight loss drug pricing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
T1INTERNATIONAL USA via T1INTERNATIONAL USA
2024 · second_quarter · Q2
S. 954 Affordable Insulin Now Act of 2023 and related administrative action
Filing targets: Federal Trade Commission (FTC), SENATE
T1INTERNATIONAL USA via T1INTERNATIONAL USA
2024 · first_quarter · Q1
The Affordable Insulin Now Act (SB 954); Improving Needed Safeguards for Users of Lifesaving Insulin Now Act of 2023 or the INSULIN Act of 2023 (SB 1269)
Filing targets: SENATE
T1INTERNATIONAL USA via T1INTERNATIONAL USA
2023 · fourth_quarter · Q4
S. 954 Affordable Insulin for All Act of 2023; S. 727 Insulin for All Act of 2023
Filing targets: SENATE
T1INTERNATIONAL USA via T1INTERNATIONAL USA
2023 · third_quarter · Q3
S. 954 Affordable Insulin for All Act of 2023; S. 727 Insulin for All Act of 2023; Public Production Policies including the forthcoming Affordable Drug Manufacturing Act of 2023
Filing targets: SENATE
T1INTERNATIONAL USA via T1INTERNATIONAL USA
2023 · second_quarter · Q2
S. 954 Affordable Insulin for All Act of 2023; S. 727 Insulin for All Act of 2023; S. 150 Affordable Prescriptions for Patients Act of 2023; S. 148 Stop Stalling Act of 2023; S. 142 Preserve Access to Affordable Generics & Biosimilars Act; S. 113 Prescription Pricing for the People Act of 2023; S. 79 Interagency Patent Coordination and Improvement; S. 1139 Lower Drug Costs for Families Act of 2023; S. 1264 Smart Prices Act of 2023; ISLET Act; Supplies Act (Forthcoming Bill); S. 1283 Tax on Wall Street Speculation Act of 2023.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
T1INTERNATIONAL USA via T1INTERNATIONAL USA
2023 · first_quarter · Q1
Insulin for All Act of 2023 (H.R. 1485/S. 727); Affordable Insulin Now Act of 2023 (S. 954)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
T1INTERNATIONAL USA via T1INTERNATIONAL USA
2022 · fourth_quarter · Q4
Affordable Insulin Now Act (H.R.6833/S.3700); Affordable Insulin for All Act (no bill number)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
T1INTERNATIONAL USA via T1INTERNATIONAL USA
2022 · third_quarter · Q3
Affordable Insulin Now Act (H.R.6833/S.3700); Affordable Insulin for All Act (no bill number); NDAA (Public Production Amendment 203); Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act (no bill number)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
T1INTERNATIONAL USA via T1INTERNATIONAL USA
2022 · second_quarter · Q2
Restoring the America Invents Act (S.2891)
Build Back Better Act (H.R.5376); Affordable Insulin Now Act (H.R.6833/S.3700); Affordable Insulin for All Act (no bill number)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
T1INTERNATIONAL USA via T1INTERNATIONAL USA
2022 · first_quarter · Q1
Restoring the America Invents Act (S.2891)
Build Back Better Act (H.R.5376); Affordable Insulin Now Act (H.R.6833/S.3700); Affordable Insulin for All Act (no bill number)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
T1INTERNATIONAL USA via T1INTERNATIONAL USA
2021 · fourth_quarter · Q4
Build Back Better Act (H.R.5376); Elijah E. Cummings Lower Drug Costs Now Act (H.R.3); Insulin Affordability for All Act (no bill number)
Build Back Better Act (H.R.5376); Elijah E. Cummings Lower Drug Costs Now Act (H.R.3); Insulin Affordability for All Act (no bill number)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE